港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单

智通财经01-02

智通财经APP获悉，恒瑞医药(01276)午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2(CLDN18.2)的抗体药物偶联物(ADC)——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2600056352?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-02 13:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600056352","market":"sh","top_or_hot":-1,"title":"港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，恒瑞医药(01276)午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2(CLDN18.2)的抗体药物偶联物(ADC)——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388110.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-02 13:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1388110.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，恒瑞医药(01276)午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2(CLDN18.2)的抗体药物偶联物(ADC)——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388110.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2543165471.USD","symbol_name":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1388110.html","article_id":"2600056352","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600056352","pubTimestamp":1767332632,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，恒瑞医药午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2的抗体药物偶联物——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0196":"行业龙头","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK4231":"零售房地产信托","BK0239":"医药制造","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK4080":"零售业房地产投资信托","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","01276":"恒瑞医药","ADC":"艾格里房产","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","BK0028":"国家队","LU0359201612.USD":"贝莱德中国基金A2","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1191":"制药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0060":"抗癌","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC"},"translate_title":"Changes in Hong Kong stocks | Hengrui Medicine (01276) rose more than 5% in the afternoon CLDN18.2 ADC gastric cancer indications were included in the list of breakthrough treatment products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5,"ADC":1.5},"content_text":"智通财经APP获悉，恒瑞医药(01276)午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2(CLDN18.2)的抗体药物偶联物(ADC)——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。根据公告，此次纳入突破性治疗程序基于该药物在特定适应症上的潜在临床价值。药审中心将为此药物优先配置审评资源，加强研发指导，以加速其临床开发和上市进程。胃癌是中国高发恶性肿瘤，2020年国内新发与死亡病例分别占全球约44%和48.6%，存在巨大的未满足临床需求。CLDN18.2靶点在多种消化道肿瘤中高表达，是目前肿瘤药物研发的热门靶点之一，全球范围内尚无同类ADC产品获批上市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600056352","isCrawlerRequest":true}